<DOC>
	<DOCNO>NCT03013985</DOCNO>
	<brief_summary>The purpose study find treatment Glargine U300 compare Glargine U100 result similar sugar control patient Type 2 Diabetes ( T2D ) , admit hospital transition home , discharge hospital .</brief_summary>
	<brief_title>Glargine U300 Hospital Trial</brief_title>
	<detailed_description>Several randomize clinical trial do previously medicine surgical patient T2D show basal bolus regimen glargine result low mean daily blood glucose ( BG ) concentration compare sole use slide scale regular insulin ( SSI ) low rate hospital complication . Glargine U300 result similar improvement lower rate hypoglycemia treatment glargine U100 . No previous study ; however , compare efficacy safety glargine U300 management hyperglycemia diabetes hospital setting . This study determine treatment glargine U300 similar glucose control patient diabetes admitted hospital glargine U300 result lower number low blood sugar compare glargine U100 .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Males female &gt; 18 year admit general medicine surgical service . Known history T2D treat either diet alone , oral monotherapy , combination oral antidiabetic agent , shortacting GLP1RA ( exenatide , liraglutide ) insulin therapy exception degludec glargine U300 . Subjects must admission/randomization BG &gt; 140 mg &lt; 400 mg/dL without laboratory evidence diabetic ketoacidosis ( bicarbonate &lt; 18 mEq/L , pH &lt; 7.30 , positive serum urinary ketone ) . Subjects increase BG concentration , without know history diabetes . Subjects history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ( 40 ) . Patients treat degludec glargine U300 , longacting weekly GLP1RA ( weekly exenatide , dulaglutide albiglutide ) . Patients acute critical surgical illness admit ICU expect require admission ICU . Patients clinically relevant hepatic disease ( diagnose liver cirrhosis portal hypertension ) , corticosteroid therapy , impaired renal function ( eGFR &lt; 30 ml/min ) . Mental condition render subject unable understand nature , scope , possible consequence study . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Blood glucose</keyword>
</DOC>